Research Article| Volume 61, ISSUE 1, P89-93, January 2023

Download started.


Botulinum toxin in the management of myalgia in temporomandibular disorders: are all injections equal?

Published:November 29, 2022DOI:


      Botulinum toxin (BTX) is becoming widely used as an adjunct to conservative management of myalgia-predominant temporomandibular disorders (TMDs) with reports of improved quality of life. There is, however, no consensus on the optimal dosage. Based on previous studies, dose regimens vary between clinicians, and we know of no standard dose protocol for the administration of BTX for the purpose of TMD management. A survey was sent to members of the British Association of Oral and Maxillofacial Surgeons (BAOMS) Temporomandibular Joint Sub-Specialty Interest Group (TMJ SSIG) and an international mailing list of high-volume TMJ surgeons (the TMJ Internetwork) to ascertain variations in dose regimens between different clinicians. The survey found that 41 respondents offered BTX to patients. The masseter muscle group was the most commonly injected site, and the majority of respondents (34/41) used Botox® (Allergan). Brands less commonly used included Dysport® (Ipsen), and Xeomin® (Merz Pharma). Botox® doses varied between 30 and 100 units, whilst Dysport® doses ranged from 50 - 300 units/muscle. The number of injection sites/muscle also varied. This survey demonstrates the wide variation in practice amongst clinicians with respect to BTX administration. To ensure optimal dose and response titration, further studies and evidence-based research are needed to standardise its use for the treatment of TMDs.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to British Journal of Oral and Maxillofacial Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Durham J, Aggrawal V, Davies SJ, et al. Temporomandibular disorders (TMDs): an update and management guidance for primary care from the UK Specialist Interest Group in Orofacial Pain and TMDs (USOT). Royal College of Surgeons of England, 2013 (Clinical Standard Series).

      2. National Institute of Dental and Craniofacial Research. Facial pain. Available from URL: (last accessed 5 December 2022).

        • Valesan L.F.
        • Da-Cas C.D.
        • Réus J.C.
        • et al.
        Prevalence of temporomandibular joint disorders: a systematic review and meta-analysis.
        Clin Oral Invest. 2021; 25: 441-453
        • Maixner W.
        • Diatechenko L.
        • Dubner R.
        • et al.
        Orofacial pain prospective evaluation and risk assessment study: the OPPERA study.
        J Pain. 2011; 12 (T4-11.e1-2)
        • Hoffmann R.G.
        • Kotchen J.M.
        • Kotechen T.A.
        • et al.
        Temporomandibular disorders and associated clinical comorbidities.
        Clin J Pain. 2011; 27: 268-274
        • Woolf C.J.
        Central sensitization: implications for the diagnosis and treatment of pain.
        Pain. 2011; 152: S2-S
        • Schiffman E.
        • Ohrbach R.
        • Truelove E.
        • et al.
        Diagnostic criteria for temporomandibular disorders (DC/TMD) for clinical and research applications: recommendations of the International RDC/TMD Consortium Network and Orofacial Pain Special Interest Group.
        J Oral Facial Pain Headache. 2014; 28: 6-27
        • Zakrzewska J.M.
        Differential diagnosis of facial pain and guidelines for management.
        Br J Anaesth. 2013; 111: 95-104
        • Dressler D.
        Clinical pharmacology of botulinum toxin drugs.
        Handb Exp Pharmacol. 2021; 263: 93-106
      3. National Institute for Health and Care Excellence. Temporomandibular disorders (TMDs). Available from URL: (last accessed 5 December 2022).

      4. Royal College of Physicians. Spasticity in adults: management using botulinum toxin. National guidelines 2018. Available from URL: file:///C:/Users/User/Downloads/Spasticity%20in%20adults_final%20version_March%202019.pdf (last accessed 5 December 2022).

      5. National Institute for Health and Care Excellence. Botulinum toxin type A. Available from URL: (last accessed 5 December 2022).

        • Villa S.
        • Raoul G.
        • Machuron F.
        • et al.
        Improvement in quality of life after botulinum toxin injection for temporomandibular disorder.
        J Stomatol Oral Maxillofac Surg. 2019; 120: 2-6
        • Thambar S.
        • Kulkarni S.
        • Armstrong S.
        • et al.
        Botulinum toxin in the management of temporomandibular disorders: a systematic review.
        Br J Oral Maxillofac Surg. 2020; 58: 508-519
        • Ernberg M.
        • Hedenberg-Magnusson B.
        • List T.
        • et al.
        Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: a randomized, controlled, double-blind multicenter study.
        Pain. 2011; 152: 1988-1996
        • Guarda-Nardini L.
        • Manfredini D.
        • Salamone M.
        • et al.
        Efficacy of botulinum toxin in treating myofascial pain in bruxers: a controlled placebo pilot study.
        Cranio. 2008; 26: 126-135
        • Kurtoglu C.
        • Gur O.H.
        • Kurkcu M.
        • et al.
        Effect of botulinum toxin-A in myofascial pain patients with or without functional disc displacement.
        J Oral Maxillofac Surg. 2008; 66: 1644-1651
        • Nixdorf D.R.
        • Heo G.
        • Major P.W.
        Randomized controlled trial of botulinum toxin A for chronic myogenous orofacial pain.
        Pain. 2002; 99: 465-473
        • von Lindern J.J.
        • Niederhagen B.
        • Bergé S.
        • et al.
        Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity.
        J Oral Maxillofac Surg. 2003; 61: 774-778
        • Serrera-Figallo M.A.
        • Ruiz-de-León-Hernández G.
        • Torres-Lagares D.
        • et al.
        Use of botulinum toxin in orofacial clinical practice.
        Toxins (Basel). 2020; 12: 112
        • Patel A.A.
        • Lerner M.Z.
        • Blitzer A.
        Incobotulinum toxin A injection for temporomandibular joint disorder.
        Ann Otol Rhinol Laryngol. 2017; 126: 328-333
        • Chen Y.W.
        • Chiu Y.W.
        • Chen C.Y.
        • et al.
        Botulinum toxin therapy for temporomandibular joint disorders: a systematic review of randomized controlled trials.
        Int J Oral Maxillofac Surg. 2015; 44: 1018-1026
      6. EMC. BOTOX 100 Units - Summary of product characteristics (SmPC). Available from URL: (last accessed 5 December 2022).

        • Dressler D.
        Clinical presentation and management of antibody-induced failure of botulinum toxin therapy.
        Mov Disord. 2004; 19: S92-S
        • Kessler K.R.
        • Skutta M.
        • Benecke R.
        • et al.
        Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group.
        J Neurol. 1999; 246: 265-274
        • Lim E.C.
        • Seet R.C.
        Botulinum toxin: description of injection techniques and examination of controversies surrounding toxin diffusion.
        Acta Neurol Scand. 2008; 117: 73-84
        • De la Torre C.G.
        • Alvarez-Pinzon N.
        • Muñoz-Lora V.R.
        • et al.
        Efficacy and safety of botulinum toxin type A on persistent myofascial pain: a randomized clinical trial.
        Toxins (Basel). 2020; 12: 395
        • Samadzadeh S.
        • Brauns R.
        • Hefter H.
        The extreme ends of the treatment response spectrum to botulinum toxin in cervical dystonia.
        Toxins (Basel). 2020; 13: 22
        • Schwartz M.
        • Freund B.
        Treatment of temporomandibular disorders with botulinum toxin.
        Clin J Pain. 2002; 18: S198-S203
      7. National Institute for Health and Care Research. 22/33 botulinum toxin in the management of chronic masticatory myofascial pain. Available from URL: (last accessed 5 December 2022).